● Pivotal Phase III study results for biosimilar candidate BI 695501 will be presented for the first time at the Annual European Congress of Rheumatology (EULAR 2017)
● Phase III results complete the total body of evidence required to demonstrate biosimilarity to HUMIRA®
● BI 695501 currently under review by regulatory authorities
INGELHEIM, Germany & MADRID-Wednesday, June 14th 2017 [ ME NewsWire ]
(BUSINESS WIRE)-- Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.
These data confirm the clinical efficacy equivalence of BI 695501 to HUMIRA®. The safety and immun
Read more »